Cupid Q1 profit nearly triples to ₹44 crore as revenue tops ₹155 crore
Consumer healthcare and FMCG company Cupid reported Q1 revenue of ₹155 crore, up from ₹60 crore a year earlier, and EBITDA of ₹60 crore. The company is expanding modern-trade, organised-retail and pharmacy distribution, plans a minimum 10% export price increase, and expects to commission its Palava facility in Q2 FY27.
What happened
Indian consumer healthcare and FMCG company Cupid nearly tripled Q1 profit to ₹44 crore as revenue more than doubled. It raised FY27 guidance, expanded
Key facts
- Q1 net profit ₹44 crore, versus ₹15 crore a year earlier
- Revenue ₹155 crore, versus ₹60 crore a year earlier
- EBITDA ₹60 crore
- Minimum 10% price increase across export portfolio
- FY27 revenue guidance ₹725 crore-₹750 crore
- FY27 net profit guidance ₹210 crore-₹225 crore
Why this matters
Cupid’s planned Palava commissioning, 10% minimum export price increase and wider retail/pharmacy reach create potential partnership opportunities across distribution, manufacturing and international market access.
What to watch
- Quarterly revenue run-rate versus the ₹725-₹750 crore FY27 target.
- EBITDA margin after modern-trade listing fees, promotional spending and channel commissions.
- Export volumes and realised pricing following the planned minimum 10% increase.
- Palava facility commissioning timing, capacity ramp and any regulatory or validation updates.
- Receivable days, inventory build and operating cash conversion as organised retail expands.
- Repeat orders, pharmacy penetration and modern-trade same-store sell-through.
- Prioritise pharmacy and modern-trade replenishment data to distinguish shipment growth from sustained consumer sell-through.
- Use export price increases selectively by market and contract cycle to protect volumes while lifting realisations.
- Build inventory and distributor credit controls before broadening organised-retail coverage, limiting working-capital stress.
- Ensure Palava facility commissioning includes qualified capacity, regulatory approvals and contingency manufacturing plans before Q2 FY27.
- Increase brand and category investment in high-repeat consumer healthcare lines to defend shelf space as distribution widens.